ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Single-cell and bulk transcriptomic profiling of metabolism-related lncRNAs reveals tumor heterogeneity and prognostic markers in non-small cell lung cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNon-small cell lung cancer (NSCLC), including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), exhibits marked tumor heterogeneity and poor prognosis. Metabolic reprogramming is a hallmark of cancer, and long non-coding RNAs (lncRNAs) have emerged as important regulators of tumor metabolism and immune interactions. This study aimed to systematically characterize metabolism-related lncRNAs in NSCLC using single-cell and bulk transcriptomic data, and to evaluate their associations with tumor heterogeneity, immune microenvironment, and clinical outcomes.
methodsRNA sequencing and clinical data for LUAD and LUSC were obtained from The Cancer Genome Atlas. Metabolism-related lncRNAs were identified through partial correlation analysis combined with KEGG pathway-based gene set enrichment analysis. Tumor microenvironment characteristics were assessed using CIBERSORTx. Consensus clustering based on the top 20 metabolism-related lncRNAs was applied to define molecular subtypes. Cis- and trans-regulatory relationships were explored using Spearman correlation, and competing endogenous RNA networks were constructed by integrating TargetScan-predicted miRNA-mRNA interactions. Findings were validated across six independent datasets, and single-cell transcriptomic data were used to assess cell-type-specific expression patterns.
resultsA subset of metabolism-related lncRNAs was significantly enriched among differentially expressed and survival-associated lncRNAs in NSCLC. AL365181.2 was identified as a key lncRNA associated with multiple metabolic pathways and poor prognosis. Single-cell analysis revealed immune cell-specific expression patterns, particularly in B cells, CD8
conclusionsMetabolism-related lncRNAs contribute substantially to tumor heterogeneity and prognosis in NSCLC and may serve as valuable biomarkers for patient stratification and personalized therapeutic strategies.
Indexed as
Identifiers
41779351What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.